& Christie, M
doi: 10.3389/fnut.2024.1398059 Received 08 March 2024 Accepted 12 April 2024 Published 29 April 2024 Volume 11 - 2024 Edited by Jorge Carriel Mancilla, Catholic University of Santiago de Guayaquil, Ecuador Reviewed by Ludwig Roberto lvarez Crdova, Catholic University of Santiago de Guayaquil, Ecuador Janeth Castano Jimenez, Indiana University Bloomington, United States Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2024 Tamayo-Trujillo, Ruiz-Pozo, Cadena-Ullauri, Guevara-Ramrez, Paz-Cruz, Zambrano-Villacres, Simancas-Racines and Zambrano
J Diabetes Res 2018:4020492
Doses shown on the platform include 1mg, 2mg, and 2.5mg (availability varies by prescription and provider)
It is a triple receptor agonist, meaning it targets three appetite-regulating hormones in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon